Advanced Solid Tumors
Trial results demonstrate safety, tolerability of HGS-ETR1 in advanced cancers
Published in Biotech Business Week, October 25th, 2004
Human Genome Sciences, Inc., (HGSI) announced that the results of ongoing phase I clinical trials demonstrate the safety and tolerability of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL Receptor 1) in patients with advanced solid tumors or non-Hodgkin lymphoma, and support further evaluation of HGS-ETR1 in phase II clinical trials, both as a single agent and in combination with chemotherapy.
Safety, pharmacokinetic, and biological activity data from two phase I studies of HGS-ETR1 were presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
The conference is jointly organized by...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Cancer Therapy
NIH grant to be used for dendritic cell-based cancer vaccines - Heart Disease
Statement on heart scans could affect 100 million Americans - Lung Cancer
FDA grants fast track status for L-BLP25 liposome cancer vaccine - Obesity
Bariatric surgery study finds typical patient still obese 3 years after surgery - Orthopedics
Orthopedic industry symposium identifies challenges, opportunities - Smallpox
Second U.S. contract awarded for smallpox vaccine - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
